Sex differences in autoimmune diseases

Rhonda Voskuhl

Abstract
Women are more susceptible to a variety of autoimmune diseases including systemic lupus erythematosus (SLE), multiple sclerosis (MS), primary biliary cirrhosis, rheumatoid arthritis and Hashimoto’s thyroiditis. This increased susceptibility in females compared to males is also present in animal models of autoimmune diseases such as spontaneous SLE in (NZBxNZW)F1 and NZM.2328 mice, experimental autoimmune encephalomyelitis (EAE) in SJL mice, thyroiditis, Sjogren’s syndrome in MRL/Mp-lpr/lpr mice and diabetes in non-obese diabetic mice. Indeed, being female confers a greater risk of developing these diseases than any single genetic or environmental risk factor discovered to date. Understanding how the state of being female so profoundly affects autoimmune disease susceptibility would accomplish two major goals. First, it would lead to an insight into the major pathways of disease pathogenesis and, secondly, it would likely lead to novel treatments which would disrupt such pathways.

Why study sex differences?
Translational research which starts with a clinical observation, such as the increased susceptibility to autoimmune disease in females, can be termed as a ‘bedside to bench to bedside approach’. In contrast to the classic ‘bench to bedside’ approach, research that begins with a clinical observation carries less inherent risk of failure. In the ‘bench to bedside’ approach, a molecule of interest is focused upon as a target to either block or enhance because it is thought to be either disease promoting or inhibiting, respectively. This is an immune molecule in the case of autoimmune diseases. The inherent risk of this approach is that, while a molecule of interest may be key to a pathway in an in vitro culture, it may not be key in vivo in the animal model due to redundant molecular pathways that exist in vivo. Further, even when a molecule of interest appears to be important in disease pathogenesis in a given animal model, it may not be critical in human disease due to differences in disease pathways in the outbred human population. Thus, the vast majority of research avenues focusing on a given molecule of interest do not ultimately prove to be physiologically significant in human disease. This results in very high costs for research and development as only a few make it to the market as new treatments. In contrast, the ‘beside to bench to bedside’ approach begins with a clinical observation that is known to be physiologically relevant in the human disease. For example, in autoimmune disease, a major disease susceptibility factor is the state of being female. If this were understood, one would have discovered something that is indeed physiologically significant. In order to understand why being female confers increased susceptibility, one must next go to the bench, using in vitro and in vivo systems to simulate this clinical observation and dissect out its underlying aetiology. After one or more molecules have been discovered which are responsible for conferring increased susceptibility of females, one can then go back to the bedside in the form of a clinical trial to test whether targeting these molecules results in disease modification. Since the ‘beside to bench to bedside’ research avenue initially began with a known clinical observation, the risk that treatments targeting pathways underlying this observation will be clinically insignificant is reduced.

Notably, the study of sex differences is important for both women and men with autoimmune diseases. The goal of this research is not merely to discern what is makes women more at risk but also what makes most men less at risk. If a factor were identified in men that confers disease protection in most, this may lead to insight into why some males do, indeed, develop autoimmune disease.
Barriers to studying sex differences in translational research

Powerful tools have been developed to unravel mechanisms underlying sex differences in diseases. Sex hormones and/or sex-linked gene inheritance may be responsible for the enhanced susceptibility of females to autoimmune diseases. As will be discussed in detail below, genetically modified mice and molecular reagents can be used to separate out sex hormone effects from sex chromosome effects, as well as to identify which hormone receptor or sex chromosome gene is involved in a given process. Meanwhile, powerful observational analyses of sex differences in a range of diseases are beginning applied to data collected anecdotally as well as in clinical trials.

Why, in light of the wealth of data on clinical observations and the sophistication of tools needed to ascertain mechanisms of sex differences, are there so few current clinical trials based on sex differences research? A major obstacle is that large clinical trials are very costly and companies must be able to recover these costs by marketing products for the years during which patent protection exists. Indeed, patent products are in place for novel molecules of interest in the classic ‘bench to bedside’ approach extremely early during development. Unfortunately, treatments evolving from insights made through the study of sex differences may ultimately entail the use of a product which cannot be patented. For example, if a naturally occurring hormone is the ultimate treatment identified, it cannot be patent protected. Thus, even if trials with a hormone were successful clinically, costs for large clinical trials would be difficult to recover. Therefore, for financial reasons, once it becomes clear that a product patent is not attainable, development of a given product by a company can be either halted or, perhaps, not even pursued.

Development of products that cannot be patent protected would ultimately produce relatively inexpensive treatments. This would be good for healthcare costs at for both the individual and the population as a whole. While some sex differences basic research and clinical trials are funded by nonprofits agencies and philanthropy, the level is far less than that undertaken by the pharmaceutical industry.

Finally, finding a new use for an old drug, development of generics or other non-patentable products for a new indication has a safety advantage. These drugs have been used in hundreds of thousands of patients for decades and their safety profile is well characterized, often with vast post marketing experience. Novel molecules that are discovered, patented and developed by a pharmaceutical company are in their relative infancy with respect to their safety profile. Generally, they are initially given to a few subjects for a few weeks and then ultimately given to, at most, a few thousand subjects for 1-2 years in order to attain the Food and Drug Administration approval. Unfortunately, during the post marketing experience, after thousands of patients have been treated for longer periods of time, serious adverse effects and even some deaths can occur.

Generally, sex differences research can lead to new insights and treatments that will be more likely to have clinically significant effects, will be safer and less expensive.

The approach for studying sex differences using multiple sclerosis (MS) as an example

This review will focus on the disease MS as an example of how one may use the ‘bedside to bench to bedside’ approach. It outlines how one may take advantage of the currently available information on clinical observations of sex differences in the disease, utilize powerful tools to dissect out basic mechanisms and then translate these findings to clinical trials. Thus, a brief description of MS and its disease model will be presented below.

MS is a putative autoimmune demyelinating disease. The target organ of the immune response is the central nervous system (CNS). Clinically, patients present with discrete episodes of neurological dysfunction which initially improve over weeks to months. This is a relapse. Hence, the early phase of the disease is the relapsing remitting phase (RR) of MS. The RR MS is characterized by large numbers of enhancing lesions on brain magnetic resonance imaging (MRI) which are thought to be biomarkers for inflammatory foci pathologically and relapses clinically. Enhancing lesions resolve about after 1-2 months and leave behind a hyperintensity on T2 weighted imaging that may reflect scarring. Clinically, over the course of weeks to months, complete or partial recovery of function occurs after a relapse. This RR phase of the disease is thought to be principally driven by the inflammatory lesions and, indeed, this early phase of MS has been shown to be responsive to anti-inflammatory treatments such as interferons [1-5]. Unfortunately, after years of carrying the diagnosis of RR MS (5-15 years), most patients ‘transition’ to a more permanently debilitating form of the disease. This later stage is called the secondary progressive phase (SP) of MS. Patients with SP MS have fewer enhancing lesions and fewer relapses, but the relapses they have are associated with poorer recovery. On magnetic resonance imaging MRI atrophy accumulation becomes apparent. There is also a progression of disability, even in the absence of clear relapses, and less responsiveness to anti-inflammatory medications [6,7].
There is a poor correlation with disability and inflammation on MRI and a better correlation between disability and atrophy. Anti-inflammatory therapies, which reduce enhancing lesions on MRI and clinical relapses, may delay atrophy and permanent disability accumulation if taken early in disease but they do not prevent the development of either. In summary, the RR MS phase is considered to be a more inflammatory phase of the disease, while the SP MS phase is a more neurodegenerative phase.

As is the case with most autoimmune diseases, one must consider the processes in both the immune response and the target organ. With regard to the immune response, MS has long been considered to be mediated by myelin protein-specific CD4+ T lymphocytes secreting T helper 1 (Th1) type cytokines such as interferon gamma (IFNγ) [8]. T lymphocytes and macrophages infiltrate the CNS and secrete pro-inflammatory cytokines such as IFNγ, interleukin-12 (IL-12), tumour necrosis factor (TNFα) and IL-17 which then sets off a cascade of events ultimately leading to demyelination of axons. This acute demyelination leads to a conduction block of neurons and clinical relapse results [9]. In contrast to the deleterious Th1 responses described above, Th2 responses, which include the production of cytokines such as IL-4, IL-5 and IL-10, are thought to be beneficial in MS. In murine systems, Th1 and Th2 immune responses are counter regulatory and, in states of health, the two responses exist in a delicate balance [10]. While there are clearly some differences in human and murine systems, therapies for MS have nevertheless aimed to either reduce Th1 or Th17 responses or to increase Th2 responses. While the currently available therapies with proven benefit in RR MS (interferon beta 1b, interferon beta 1a and copolymer-1) have numerous possible mechanisms of action, several reports indicate that they act, at least in part, through inducing favourable changes in the production of these cytokines [11-14]. Other mediators of MS include chemokines and adhesion molecules which play a role in the recruitment of immune cells from the blood to the CNS lesion foci. Tysabri, a drug which blocks adhesion molecules, was shown to reduce relapses in MS [15]. Other immune mechanisms in MS involve a variety of costimulatory molecules. Trials to determine if blocking co-stimulatory molecules may result in clinical benefit are ongoing. Finally, as autoantigen presentation by macrophages and dendritic cells in the peripheral immune system, as well as by CNS resident microglia or astrocytes, may be involved in ongoing inflammation, strategies to prevent antigen presentation by these cells are also being pursued as potential treatments.

As stated above, anti-inflammatory treatments have been shown to reduce relapses in MS but have had only a modest effect on halting the accumulation of permanent disability. Particularly later in the disease, disability accumulation has continued, despite robust and effective immunosuppression with chemotherapeutic agents [16]. Thus, MS has both an inflammatory and a neurodegenerative component in its pathogenesis. Over the last decade abundant neuroimaging and neuropathological studies have described the significant neurodegenerative process in MS. Neuroimaging has demonstrated atrophy [17-22], particularly in grey matter [21,23,24]. This grey matter atrophy has been shown to correlate better with permanent disability than the white matter inflammatory marker of gadolinium enhancing lesions [6,19,21]. Also, abnormalities beyond classic white matter T2 hyperintensities, within ‘normal appearing white matter’ (NAWM), have been seen using magnetization transfer, spectroscopy and diffusion weighted imaging [25-31]. Furthermore, the degree of change in the NAWM may be a predictor of future clinical progression [32]. Pathological findings in MS have described cortical lesions that were characterized by transected neurites (both axons and dendrites) and apoptosis. There was very little T and B cell infiltration. Activated microglia ensheathed apical dendrites, neurites and neuronal perikarya [33,34]. Axonal transection has also been described within white matter lesions raising the possibility of Wallerian degeneration in white matter tracts. In light of these clinical, neuroimaging and neuropathologic observations there is now a consensus by MS investigators that there is a need to discover a treatment which is primarily designed as a neuroprotective agent for MS. This neuroprotective agent should be taken in combination with an anti-inflammatory treatment. Theoretically, combination treatment with both an anti-inflammatory agent and a neuroprotective agent would have a greater impact upon the halting of permanent disability accumulation in MS compared to treatment with an anti-inflammatory agent alone.

Sex differences in MS

During reproductive ages (18-40), there is a distinct female preponderance of autoimmune diseases including MS [35]. Sex hormones and/or sex chromosomes may be responsible for this enhanced susceptibility. In males, the onset of MS tends to be relatively later in life (30-40), coinciding with the beginning of the decline in bioavailable testosterone (T) [36]. Thus, the female to male ratio is greater in patients presenting with MS before 20 years old (3:2:1) compared to the ratio in the MS population as a whole (2:1) [37]. Interestingly, a recent Canadian study found a disproportionate increase in the incidence of MS in women [38]. This increase in the sex ratio, approaching 4:1, was theorized to possibly be of environmental origins. Alternatively, these data...
showing an increase in diagnosis of women with MS may merely be reflective of the propensity for neurologists to diagnose women with autoimmune disease. As time passes, neurologists have more sensitive tools for detecting early MS and with these come a growing appreciation of the importance of early treatment in slowing disability accumulation. Notably, the relatively higher sex ratios in MS recently reported remain consistent with the sex ratios that were previously known in other autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).

In general, it has been well documented that women have more robust immune responses than men [39]. Females have a greater humoral response, as evidenced by higher serum immunoglobulin concentrations than males and a greater antibody response to various antigens after immunization [40]. In addition, females reject skin allografts faster and have a reduced incidence of tumours, indicating that they also have a greater cellular immune response [35]. This is also true when comparing women and men with MS. Autoantigen (proteolipid protein) specific immune responses from women were characterized by higher levels of Th1 responses [41-43]. On the other hand, it is still a controversial whether the disease course differs between the sexes remains controversial. Despite the more robust immune responses in women, some studies have suggested that men may have a more progressive course of disease [36,44,45]. Further, early neuroimaging studies suggested that women have more inflammatory markers in the CNS, while men have more neurodegenerative outcomes [46]. However, when both the clinical and neuroimaging data were adjusted for age, these sex differences in progression and neurodegenerative outcomes became less apparent. Together, these observations suggest that, while susceptibility and immune responses are higher in women than in men with MS, the rate of progression and neurodegeneration may, surprisingly, be no different. Thus, sex differences in the CNS should be considered independently of sex differences in the immune system in MS, with the potential for opposing influences.

The murine model of MS

While there is no perfect animal model of MS, experimental autoimmune encephalomyelitis (EAE) is the most widely used animal model for studying the pathogenesis of MS. Decades of work have described the immunology and the neuropathology of EAE. Immunologic studies focused on myelin protein specific immune responses including those directed against myelin basic protein (MBP), proteolipid protein (PLP) and myelin oligodendrocyte protein (MOG). Much of what has been theorized in MS with respect to immune responses was based on the initial findings in EAE, including the role for Th1 cytokines, IL17, chemokines, adhesion molecules and co-stimulatory molecules. Regarding the neuropathology of EAE, past studies focused on detailed characterization of lesions with respect to the inflammatory infiltrate composition, the level of demyelination, the level of oligodendrocyte loss, microglial activation and astrocytic scar formation [47-50]. Less attention has focused on neurons, with only recent descriptions of a relationship between axonal loss and disability [51]. Our group and others have each described CNS pathology beyond the lesion in normal appearing white matter characterized by decreases in axon densities in white matter tracts of the dorsal spinal cord [52-54]. Another study described motor neuron dendritic abnormalities in grey matter of spinal cords of mice with EAE [55] and our group has published that neuronal staining in spinal cord grey matter is abnormal even early during the course of EAE [53]. Regarding neuroimaging beyond the lesion in EAE, diffusion tensor imaging (DTI) changes have been described in dorsal cord and optic nerve by others [52,56] and cerebellar grey matter atrophy has been described by our group [57]. Thus, while EAE has been the prototypic Th1 mediated disease tool used by immunologists for decades, more recently, EAE has also been characterized with respect to its neurodegenerative component by neuroscientists.

Sex differences in the murine model of MS

EAE in the SJL strain of mice has been characterized to have a sex bias that parallels that of multiple sclerosis, with males being less susceptible to the disease than females [58-62]. In part, this sex difference may result from the protective effects of testosterone in male mice, as suggested by studies demonstrating that the removal of physiologic levels of testosterone from male mice via castration increased disease susceptibility [63,64]. Also, in animal models of other autoimmune diseases, where a similar gender dimorphism exists (non-obese diabetic (NOD) mice, thyroiditis and adjuvant arthritis), castration was shown to increase the disease prevalence and/or the disease severity [65-68]. Further, testosterone levels have been shown to be decreased in male mice during EAE relapse [69]. Together, these data support the hypotheses that endogenous androgens may be protective at physiologic levels.

Notably, however, while the SJL, the ASW and the NZW strains of mice have an increased susceptibility to EAE in females compared to males, the B10.PL and PL/J have more susceptibility to disease in males compared to females [70], while there is no sex bias in the C57BL/6 strain [71,72]. Effects of removal of androgens in EAE have previously been shown to be dependent upon genetic background [72] and some autosomal gene
linkages to susceptibility to MS have been identified in one gender but not the other [73]. Thus, in the outbred human population, the genetic background of some, but not all, individuals may be permissive to sex effects. Importantly, since overall there is a gender difference in many autoimmune diseases in humans, we hypothesize that the incidence of relatively permissive genetic backgrounds are likely to be prevalent, not rare, occurrences.

**Testicular hormones in the MS model**

Sex differences in MS and the EAE model may be related to sex hormones, sex chromosomes or both: female sex hormones or male sex hormones may play a role. This section will discuss a possible role for male sex hormones.

To begin to test the role of endogenous androgens in MS, the EAE model was used. Since EAE in the SJL strain of mice had previously been characterized to have a gender difference that paralleled that of MS, with males being less susceptible to disease than females [61-62], the SJL strain was used. Protective effects of testosterone in male mice were shown by studies demonstrating that the removal of physiologic levels of testosterone from male mice via castration increased disease susceptibility [63-72]. Finally, testosterone levels were shown to be decreased in male mice during EAE relapse [69]. Together, these data support the hypothesis that endogenous androgens are protective at physiologic levels in these autoimmune disease models.

As the MS population is genetically heterogeneous, it was then necessary to determine whether the protective effect of endogenous androgens was a phenomenon that was unique to the SJL strain. The C57BL/6 strain was used since there was no sex bias in EAE in this strain [70-72]. Disease severity did not differ between castrated and sham C57BL/6 male mice, thereby indicating that endogenous androgens are not protective in all genetic backgrounds. A lack of a protective effect of endogenous androgens in C57BL/6 mice was found to not be due to lower endogenous levels of androgens in the C57BL/6 strain as compared to the SJL strain. Thus, equivalent levels of endogenous androgens were shown to be protective in males of one genetic background but not another [72]. This is consistent with findings that the protection from disease observed in young male mice was affected by the strain of origin of the Y chromosome [74]. Autosomal loci have been identified that control susceptibility in several clinical subtypes of EAE in both males and females [75]. A locus on chromosome 13 (eae 13) was linked to susceptibility of monophasic remitting/non-relapsing EAE in males but not females. It was hypothesized that a sex specific effect at eae 13 might be responsive to testosterone levels and, thereby, give males a greater ability to control disease once it is initiated. Interestingly, it has been shown that one gene locus, rsl, in the region of eae 13, is capable of regulating sexually dimorphic traits [76]. Therefore it is possible that endogenous androgens may be protective in a given strain depending upon eae 13 allele inheritance. Some genetic backgrounds may also carry other alleles that are more sensitive to the effect of testosterone at a given endogenous level.

Notably, a lack of protection by endogenous androgens in a given genetic background did not preclude a therapeutic effect of supplemental androgen treatment in EAE. Thus, treatment was implemented using either testosterone or 5α-dihydrotestosterone (DHT). DHT was used as it cannot be converted to oestrogens. Indeed, not only were both androgen treatments shown to be protective in gonadally intact males of a strain in which endogenous androgens were protective (SJL) but they were also protective in a strain in which endogenous androgens were not protective (C57BL/6) [72]. These data indicated that, even in genetic backgrounds that are not permissive to a protective effect of endogenous androgens, protection can still be provided by supplemental exogenous androgen treatment. This suggested that the mechanisms of disease protection may differ between endogenous physiologic androgens and supplemental supraphysiologic androgen treatment. These preclinical data laid the groundwork for clinical trials that aimed to treat males in the heterogeneous MS population with testosterone.

Mechanisms underlying the protective effects of androgens have been previously investigated, and a number of studies have delineated immunological changes in androgen treated mice [77-80]. The balance between cytokines produced by Th1 and Th2 lymphocytes is considered central to the development of EAE with Th1 cytokines (IFN-γ and IL-12) being pro-inflammatory and Th2 cytokines (IL-10, IL-4 and IL-5) being anti-inflammatory [35]. In vitro treatment of naïve T cells from Vβ8.2 TCR transgenic mice stimulated with MBP Ac 1-11 peptide in the presence of testosterone resulted in increased production of IL-10 and IL-5 and decreased production of IFN-γ [79]. T cell lines from PLP 139-151 immunized mice stimulated with PLP 139-151 in the presence of DHT also resulted in increased IL-10 and decreased IFN-γ production [79]. In vivo, androgen treatment has also been shown to effect cytokine profiles. When splenocytes from mice with EAE treated in vivo with DHT or placebo were stimulated with MBP, those from DHT treated had increased IL-10 and decreased IFN-γ [77]. Further, when splenocytes from healthy mice treated with DHT in vivo were stimulated with anti-CD3 antibody, increased levels of IL-10 and decreased levels IL-12 were observed [78]. Cytokine gene knockout mice were then used to show
that DHT directly increased IL-10 from CD4+ T lymphocytes with a subsequent indirect decrease in IL-12 [78]. Together, these data indicated that one mechanism through which exogenous androgen treatment is protective in EAE involves effects on cytokine production.

**Testicular hormones in MS**

Disease onset in females typically occurs soon after puberty. In males, disease onset usually occurs later in life (age 30-40), coinciding with the age at which serum testosterone levels begin to decline in normal healthy men [81-85]. Interestingly, this phenomenon may also be true of other autoimmune diseases. The onset of rheumatoid arthritis (RA) in men also takes place later in life with a reported fourfold increase in incidence rates in older men (ages 35-74) compared to younger men (ages 18-34). Further, the sex difference of RA in women versus men is 4:1 between ages 35-44, which decreases to 1:1:1, by age 75 [86]. Together, these observations suggested that relatively high levels of testosterone in young men after puberty may provide temporary protection from autoimmune disease onset in those men who were genetically predisposed to ultimately develop the disease.

Additionally, it has been reported that 24% of male MS patients tested had significantly lower levels of testosterone compared to age-matched healthy men [87]. The reason for the decreased testosterone levels remains unclear. It may be due to gonadal failure or to effects on the hypothalamic-pituitary axis (HPA) such as stress or hypothalamic lesions [69]. In men with MS and sexual dysfunction, low testosterone levels have been previously shown to be associated with low luteinizing hormone levels, thereby ruling out gonadal failure [69]. Interestingly, a decrease in free testosterone levels has been reported in untreated men with new onset RA [88], making the possibility of hypothalamic lesions in the brain in MS less likely. An effect of the stress of chronic illness on the HPA may be the most likely explanation for the relatively lower levels of testosterone in men with chronic autoimmune diseases.

Data in EAE suggested that supplemental, exogenous testosterone treatment may provide protection across genetic backgrounds in men of the heterogeneous MS population [72]. Thus, to investigate the possible effects of testosterone treatment in MS, testosterone was administered via transdermal application (AndroGel©) to men with RR MS in a small pilot trial [89]. A crossover design, using a within arm comparison of 6 months pretreatment to 12 months treatment, was employed to reduce the effect of disease heterogeneity given the small sample size, as previously described in MS [90].

Ten subjects with RR MS completed the study. At baseline, all subjects had testosterone levels in the lower range of normal. During daily treatment with testosterone, serum testosterone levels rose 50% on average to the higher range of normal. Scores from the Paced Auditory Serial Addition Task (PASAT) component of the Multiple Sclerosis Functional Composite (MSFC), a commonly used cognitive test in MS, remained stable during the first 6 months of treatment (months 3 and 6), trended upward after 9 months and were significantly improved by month 12 of treatment. There was also a trend for improvement in spatial memory, consistent with previous reports of testosterone mediated improvements in working and spatial memory in healthy non-hypogonadal elderly men [91,92].

The 10 subjects had low levels of enhancing lesion activity on brain MRI at baseline and this low level was not significantly increased or decreased with treatment. The most interesting finding of the study was the effect on brain atrophy. There was a 67% reduction in the rate of brain volume loss during treatment compared to that seen at pre-treatment. Interestingly, the timing of the cognitive improvements coincided with the slowing of brain atrophy on MRI.

Finally, testosterone treatment was also shown to favourably affect the immune system by inducing decreasing CD4+ T cell percentage and increasing natural killer (NK) cells. In addition, peripheral blood lymphocytes (PBMC) production of IL-2 was significantly decreased while transformin growth factor (TGF)b1 production was increased. Furthermore, PBMCs obtained during the treatment period produced significantly more of neuroprotective factors brain-derived neurotrophic factor (BDNF) and platelet-derived growth factor (PDGF-BB) [93].

In summary, endogenous androgens are protective in EAE in some strains but not others. However exogenous supplemental treatment with androgens is protective across the genetic backgrounds. In humans with MS, we hypothesize that some, but not all, men may be of a genetic background that provides the protective effect of relatively high physiologic levels of testosterone that exist in young men. This may mask the early presentation of the relapsing remitting phase of the disease. As these men age, testosterone levels gradually decline and clinical MS onset is observed. Later, during the course of disease, it is possible that the stress of chronic disease may affect the hypothalamic-pituitary axis which suppresses testosterone levels further, to within the low normal range. Further clinical trials are warranted in order to determine whether treatment with supplemental testosterone may offer some protection in men with MS.

### A second clinical observation

Ovarian hormones primarily include oestrogens and progesterone. Sex differences in MS could be due, at least in part, to sex differences in ovarian hormones.
Indeed, the onset of MS in women is after puberty. However, there is no evidence that ovariectomy precipitates or aggravates MS. In contrast to the lack of evidence that endogenous cycling levels of ovarian hormones are major disease modifiers in MS, there is abundant evidence that the state of being pregnant is associated with disease protection. The effect of pregnancy appears to be due, in part, to a protective effect of high levels of oestrogen during late pregnancy. Thus, a second major clinical observation merges: pregnancy is a major disease modifier in MS. The study of sex differences in autoimmune disease includes: (1) research addressing female: male differences in a given autoimmune disease; and (2) research focused on a major disease modifier which is inherent to being one sex. Thus, in autoimmune disease, there are two major clinical observations. First, females are more susceptible than males. Second, pregnancy reduces relapses in females. Both of these observations can be pursued with respect to basic mechanism and translational potential.

With regard to this second clinical observation, it has been appreciated for decades that symptoms of patients with autoimmune diseases are affected by pregnancy and the post partum period. The most well characterized observations include those seen in MS, RA and psoriasis. These patients experience clinical improvement during pregnancy with a temporary rebound exacerbation post partum [35,94-100]. Interestingly, women with SLE may experience an exacerbation of symptoms with gestation [101]. This differential effect of pregnancy on these diseases is thought to reflect the difference in immunopathogenesis of SLE as compared to MS and RA.

What is the precise effect of pregnancy on MS? What had been generally recognized for decades was that there was a period of relative ‘safety’ with regard to relapses during late pregnancy followed by a period of increased relapses post partum. These clinical observations were supported by a small study of two patients who underwent serial cerebral MRIs during pregnancy and post partum. In both women there was a decrease in MR disease activity (T2 lesion number) during the second half of pregnancy and a return of MR disease activity to pre-pregnancy levels in the first months post-partum [102]. Other studies found that, in addition to having a decrease in disease activity in patients with established MS, the risk of developing the first episode of MS was decreased during pregnancy compared to non-pregnant states [100]. The most definitive study of the effect of pregnancy on MS came in 1998 by the Pregnancy in Multiple Sclerosis (PRIMS) Group [96]. Relapse rates were determined in 254 women with MS during 269 pregnancies and for up to 1 year after delivery. Relapse rates were significantly reduced from 0.7 per woman year in the year before pregnancy to 0.2 during the third trimester. Rates then increased to 1.2 during the first 3 months post partum before returning to pre-pregnancy rates. No significant changes were observed between relapse rates in the first and second trimester compared to the year prior to pregnancy. Together, these data clearly demonstrated that the latter part of pregnancy is associated with a significant reduction in relapses, while there is a rebound increase in relapses post partum.

Since mechanisms of action of the approved therapies for MS involve anti-inflammatory effects and, as these treatments result primarily in a reduction in relapse rates, it is logical to hypothesize that mechanisms underlying the protective effect of pregnancy on MS relapses involve anti-inflammatory effects. Pregnancy is a challenge for the immune system. From the mother’s standpoint, the fetus is an allograft as it harbours antigens inherited from the father. It is evolutionarily advantageous for the mother to transiently suppress cytotoxic cell mediated, Th1 type immune responses involved in fetal rejection during pregnancy. However, not all immune responses should be suppressed as humoral; Th2 type immunity is needed for the passive transfer of antibodies to the fetus. Thus, a shift in immune responses with a downregulation of Th1 and an upregulation of Th2 is thought to be necessary for fetal survival [10,103-105]. Indeed, it has been shown that, in both mice and humans, failure to shift immune responses in this manner results in an increase in spontaneous abortion [104,106,107]. This shift in immune responses from Th1 to Th2 occurs both locally at the maternal fetal interface [10,108,109] as well as systemically [104,106,107,110-112]. The systemic shift away from Th1 and toward Th2 was initially shown in murine systems by a decrease in mixed lymphocyte reactions of splenocytes and an increase in antibody production during pregnancy [112]. Antigen stimulated splenocytes were then shown to produce less Th1 cytokines and more Th2 cytokines when derived from pregnant mice [106,110]. In humans, peripheral blood mononuclear cells in women with successful pregnancies produced IL10 but no IFNγ, upon stimulation with trophoblast antigens [104]. In another study, antigen- and mitogen-stimulated PBMC derived from patients with normal pregnancies demonstrated a decrease in the production of IL2 and IFNγ and an increase in production of IL4 and IL10, with the lowest quantities of IL-2 and IFNγ and the highest quantities of IL4 and IL10 present in the third trimester of pregnancy [107]. During the third trimester pregnancy, ex vivo monocytic IL12 production was also found to be about threefold lower and TNFα production was approximately 40% lower than postpartum values [111]. Two recent studies have been
completed where MS subjects were followed longitudinally for immune responses during pregnancy and post partum. Gilmore et al. demonstrated that ex vivo stimulated PBMCs had increased IFNγ production post partum as compared to the third trimester and myelin protein specific T cell lines derived from subjects in the third trimester produced more IL10 [113], while Al-Shammri et al. found that six of the eight MS patients’ ex vivo stimulated PBMCs showed a distinct shift from a Th2 cytokine bias (IL4 and IL10) during pregnancy, towards a Th1 cytokine bias (IFNγ and TNFα) after delivery [114]. In light of these data which demonstrated a relative shift to Th2 systemically during pregnancy, with a rebound back to Th1 post partum, it becomes highly plausible that these alterations in the immune response could underlie the improvement in putative Th1 mediated autoimmune diseases during pregnancy, as well as the exacerbation post partum.

Pregnancy is a complex event characterized by changes in numerous factors which may impact the CNS. These include increases in oestriol, oestradiol, progesterone and prolactin, to name a few [115]. Potential neuroprotective effects of oestrogens and progesterone will be discussed in depth below. Recently, it was shown that pregnant mice have an enhanced ability to re-myelinate white matter lesions and that prolactin regulates oligodendrocyte precursor proliferation and mimics this regenerative effect of pregnancy [116]. This finding may be potentially exploited in pursuit of a therapeutic repair strategy to increase remyelination. However, when considering the effect of prolactin treatment in neuroimmunologic diseases such as MS, one must recall that prolactin has pro-inflammatory properties which can exacerbate disease, as has been shown in the MS model, EAE [117]. Thus, when considering any pregnancy factor, its effects on both the CNS and the immune system must be considered. Notably, the clinical observation that breast feeding, which would be associated with a prolonged state of increased levels of prolactin, had no effect compared to no breast feeding with respect to the post partum rate in MS [118]. A lack of a difference in relapse rate may suggest that the pro-inflammatory properties of increased prolactin during breast feeding may not be clinically significant. On the other hand, the relapse rate is a relatively insensitive, albeit important, outcome measure. Future studies should compare immune responses, enhancing lesions on MRI and prolactin levels in MS women who are, or are not, breast feeding post partum.

What is striking about pregnancy is that it represents a state that is characterized by two important changes. First, there is a downregulation of cellular immune responses. This relative immunosuppression probably occurs in order to prevent fetal rejection. Second, pregnancy is characterized by the presence of potentially neuroprotective hormones, such as oestrogens, progesterone and prolactin. It would seem evolutionarily advantageous to have such neuroprotective factors present as neuronal and oligodendrocyte lineage cells in the fetus progress through critical developmental windows [119]. Together, the combined anti-inflammatory and neuroprotective state of pregnancy, which is, perhaps, aimed at protecting the fetus, is precisely what is needed to protect the CNS during inflammatory attack in MS.

**Treatment with ovarian hormones in EAE**

It was shown over a decade ago that EAE in guinea pigs, rats and rabbits improved during pregnancy [94]. Further, it was shown that relapsing-remitting EAE in SJL mice improved during late pregnancy [120,121]. The EAE model was then used to determine if an increase in levels of a certain hormone during pregnancy might be responsible for disease improvement. Since oestrogens and progesterone increase progressively during pregnancy to the highest levels in the third trimester, these hormones were candidates for possibly mediating a protective effect. Two oestrogens, oestradiol and oestriol, increase progressively during pregnancy. Oestradiol is otherwise present at much lower fluctuating levels during the menstrual cycle in non-pregnant women and female mice. Oestriol, in contrast, is made by the fetal placental unit and is not otherwise present in non-pregnant states. Over the last 10 years it has been shown in numerous studies that oestrogen treatment (both oestradiol and oestriol) can ameliorate both active and adoptive EAE in several strains of mice (SJL, C57BL/6, B10.PL, B10.RII1) [122-130]. Oestriol treatment has also been shown to be effective in reducing clinical signs in EAE when administered after disease onset [129]. Finally, both oestradiol and oestriol have been shown to be efficacious in both female and male mice with EAE [131].

Effects of oestrogen treatment in animal models of RA are similar to those in EAE. Oestrogen treatment is clearly protective in collagen induced arthritis (CIA) and pharmacologic blocking of both nuclear ERα and ERβ receptors abolished this protection [132-135]. In contrast, oophorectomy ameliorates murine lupus, while oestrogen treatment, even at physiologic doses, accelerates disease [136-138]. The mechanism for the deleterious effect of oestrogen on murine lupus appears to involve, at least in part, an oestrogen induced effect on genes involved in survival and apoptosis of B cells which results in a skewing of naïve B cells towards autoimmunity [139-142]. Opposite effects of oestrogen treatment in EAE and CIA, as compared to oestrogen treatment in lupus, are reminiscent of the opposite effects of pregnancy in the human autoimmune diseases they model.
The type and dose of the oestrogen used in a disease appears to be critical. A clinical amelioration of EAE occurred when oestriol was used at doses to induce serum levels which were physiologic with pregnancy. On the other hand, oestradiol had to be used at doses several fold higher than pregnancy levels in order to induce the same degree of disease protection [128]. Thus, while it is clear that high doses of oestradiol are protective in EAE, it has not yet been clearly established whether low doses of oestradiol are protective. Due to major differences in metabolic rates between humans and mice, it is very difficult to determine what a low dose oestrogen in an oral contraceptive pill in humans would equate to in a mouse. Thus, one can only use available physiologic benchmarks, such as the dose needed to induce a level in blood equal to that in pregnant mice or the dose needed to induce an oestrus level in an ovariectomized mouse. Rigorous comparisons of blood levels in pregnant or oestrus mice, assessed in parallel with levels in oestradiol treated mice are needed. Since ovariectomy removes physiologic levels of oestradiol, as well as progesterone, data on the effect of ovariectomy on EAE is somewhat informative in this regard. Some reports have found that ovariectomy of female mice makes EAE worse [125], while others have found that ovariectomy does not have a significant effect on disease [121]. Thus, it is controversial whether low levels of endogenous oestradiol which fluctuate during the menstrual cycle have a significant influence on EAE.

What is the effect of the other major ovarian hormone, progesterone, in EAE? Theoretically progesterone treatment could be beneficial as it had previously been shown in other systems to aid in myelination by oligodendrocytes [143,144]. However, while the severity of EAE was significantly reduced in oestriol or oestradiol treated mice as compared to placebo treated, treatment with progesterone was indistinguishable from the placebo [129]. A variety of progesterone doses, ranging from low (physiologic with menstrual cycle levels) to moderate (physiologic with late pregnancy levels) to very high (supraphysiologic), were used in combination with oestrogen (either oestradiol or oestriol) in EAE and none of the progesterone doses significantly altered the protective effect of oestrogen treatment on EAE disease course [121]. The lack of an effect of progesterone treatment on EAE was somewhat disappointing since progesterone had been shown to enhance remyelination in vitro [144-146]. Interestingly, in the Lewis rat, progesterone treatment alone was shown to deleterious, causing increased motor deficits, increased inflammation and increased neuronal apoptosis during acute EAE, while oestrogen treatment in combination protected against these deleterious effects of progesterone [147]. These data in EAE are consistent with previous work by the Holmdahl group in the mid 1990s which demonstrated that treatment with oestrogens could ameliorate collagen induced arthritis [128,132,135], while progesterone treatment alone had no effect. Progesterone treatment had only mild synergistic effects when used in combination with oestrogen treatment [148]. Together, these data indicate that oestrogen, not progesterone, can mediate disease protection during EAE.

Protective mechanisms of oestrogen treatment (both oestradiol and oestriol) in EAE clearly involve anti-inflammatory processes, with oestrogen treated mice having fewer inflammatory lesions in the CNS [129]. In adoptive EAE in SJL mice, an increase in IFNγ, with no change in IFNγ, was observed in ex vivo stimulated MBP specific responses, which was accompanied by an increase in MBP specific antibody of the IgG1 isotype, with no change in those of the IgG2a isotype [129]. In active EAE in C57BL/6 mice, a decrease in TNFα, IFNγ, and IL6 has been observed, with an increase in IL5 [122,123,130,131]. Oestrogen treatment has also been shown to downregulate chemokines in the CNS of mice with EAE and may affect expression of matrix metalloprotease-9 (MMP-9), each leading to impaired recruitment of cells to the CNS[125,127]. Oestradiol at pregnancy levels, but not below, reduced IL17 and increased PD-1 in T regulatory cells [149]. In addition oestrogen treatment has been shown to impair the ability of dendritic cells to present antigen [124,150]. The effect of oestrogen treatment on dendritic cell function in EAE may involve upregulated expression of indoleamine 2,3-dioxygenase (IDO) [151]. IDO is an enzyme involved in the catabolism of tryptophan which is expressed in antigen-presenting cells of lymphoid organs and in the placenta. It was shown that IDO prevents rejection of the fetus during pregnancy, probably by inhibiting alloreactive T cells [152] and it has been shown that IDO expression in antigen-presenting cells may also control autoreactive immune responses [153]. Finally, oestrogen treatment has recently been shown to induce CD4+CD25+ regulatory T cells in EAE [154,155]. Thus, oestrogen treatment has been shown to be anti-inflammatory through a variety of mechanisms.

An anti-inflammatory effect of oestrogen treatment in EAE does not preclude an additional more direct neuroprotective effect. Oestrogens are lipophilic, readily traversing the blood brain barrier, with the potential to be directly neuroprotective [156-158]. Numerous reviews have described oestrogen’s neuroprotective effects, both in vitro and in vivo [157-159] in other model systems. In vitro, oestrogens have been shown to protect neurons in a variety of models of neurodegeneration, including those induced by excitotoxicity and oxidative stress [160-163]. Treatment with oestrogen decreased glutamate-induced apoptosis and preserved electrophysiologic
function in neurons [159,164,165]. Decreased microglial activation has also been demonstrated after oestrogen treatment [166-168], along with modulation of the astrocytic response to injury [169,170]. Oestrogen treatment also protected oligodendrocytes from cytotoxicity [171-173] as well as accelerated oligodendrocyte process formation [174]. In *in vivo* studies have shown that oestrogen treatment can be neuroprotective in animal models of Parkinson’s disease, cerebellar ataxia, late onset leukodystrophy, stroke and spinal cord injury, often by reducing apoptosis via upregulation of the anti-apoptotic genes bcl-2 and bcl-x [158,159,175-181]. Oestrogens have also been shown *in vitro* and *in vivo* to increase dendritic spine formation and synapses on CA1 pyramidal cells of the hippocampus in healthy rats, resulting in improved working spatial memory [182-186].

Given the neuroprotective effect of oestrogen treatment in other disease models, it was then addressed whether oestrogen treatment might be neuroprotective in EAE, the MS model. Oestradiol treatment not only reduced clinical disease severity and was anti-inflammatory with respect to cytokine production in peripheral immune cells, it also decreased CNS white matter inflammation and demyelination. In addition, decreased neuronal staining (NeuN+/β3-tubulin +/Nissl), accompanied by increased immunolabelling of microglial/monocyte (Mac 3+) cells surrounding these abnormal neurons, was observed in grey matter of spinal cords of placebo treated EAE mice at the earliest stage of clinical disease, and treatment with oestradiol significantly reduced this grey matter pathology. Thus, oestradiol treatment was not only anti-inflammatory but also neuroprotective in the prevention of both white and grey matter pathology in spinal cords of mice with EAE [53].

Determining which oestrogen receptor mediates the protective effect of an oestrogen treatment in disease is of central importance for future development of selective oestrogen receptor modifiers which aim to maximize efficacy and minimize toxicity. The actions of oestrogen are mediated primarily by nuclear oestrogen receptors, ERα and ERβ, although non-genomic membrane effects have also been described [187]. Originally it was thought that ERα and ERβ would each have distinct tissue distributions, thereby providing a means through which use of selective oestrogen receptor modifiers (SERMs) could improve tissue selectivity. However, the relationship between ERα and ERβ became complex, with most tissues expressing detectable level of each of these receptors [188]. The two receptors at times did, and at other times did not, co-localize to the same cells within a given tissue [189,190]. Further, in some tissues the two receptors were shown to act synergistically, while in other tissues they acted antagonistically. Tissue specific differences in biologic outcomes are thought to be due, in part, to tissue specific differences in transcription factors which become activated upon binding of each oestrogen receptor (ER) by ligand [191-193].

Despite the fact that both ERα and ERβ are expressed in both the immune system and the CNS [188,189,194,195], oestrogen receptor knock out mice have been used to show that the protective effect of oestrogen treatment (oestradiol and oestriol) in EAE was dependent upon the presence of ERα, not ERβ [126,130]. However, whether targeted stimulation of ERα in developmentally normal mice was both necessary and sufficient for the oestrogen mediated protection in EAE remained unknown. A highly selective ERα ligand, propyl pyrazole triol (PPT) [196], was then used to determine whether stimulation of ERα in developmentally normal mice would be sufficient for the oestrogen mediated protection in EAE. Our group [53], and another [197], have each found that treatment with this ERα selective ligand was indeed sufficient for protection in EAE and was capable of inducing favourable changes in autoantigen specific cytokine production in the peripheral immune system (decreased TNFα, IFNγ and IL6, with increased IL5), as well as decreasing pathology in the CNS.

Subsequently, bone marrow chimeras were used by Garidou et al. to show that the disease ameliorating effects of oestradiol treatment in EAE were not dependent upon ERα signalling in blood derived inflammatory cells [198]. This suggested that the functionally significant target for oestrogen’s actions *in vivo* during EAE is cells within the CNS. Given that treatment with either oestradiol or the ERα ligand was both anti-inflammatory and neuroprotective, the central question then became whether the neuroprotective properties of oestrogen treatment in EAE were or were not dependent upon the anti-inflammatory properties. Notably, a study had suggested that an anti-inflammatory effect was necessary to observe oestrogen mediated neuroprotection in stroke [199].

Since treatment with an ERα ligand is so anti-inflammatory in the peripheral immune system of EAE mice, there is a dramatic reduction in immune cells going into the CNS. While myelin and axons are preserved in the CNS, it cannot be discerned whether the effect of ERα ligand treatment is solely anti-inflammatory (and only indirectly neuroprotective) versus whether it is both anti-inflammatory and directly neuroprotective. In this context, direct neuroprotection refers to protection of CNS cells which is not merely due to reducing the immune attack. It is very difficult to treat only the CNS with an ERα ligand and block all effects in the periphery. However, differential neuroprotective and anti-inflammatory effects of ERα and ERβ ligand treatment
revealed insights into whether oestrogen treatment might be directly neuroprotective in EAE [54]. Clinically, ERα ligand treatment abrogated disease at the onset and throughout the disease course. In contrast, ERβ ligand treatment had no effect at disease onset, but promoted recovery during the chronic phase of the disease. ERα ligand treatment was anti-inflammatory in the systemic immune system, while ERβ ligand treatment was not. However, treatment with either the ERα or the ERβ ligand was neuroprotective as evidenced by reduced demyelination and preservation of axon numbers in white matter [200,201]. Thus, by using the ERβ selective ligand, the anti-inflammatory effect from the neuroprotective effect of oestrogen treatment were dissociated and it was shown that neuroprotective effects of oestrogen treatment were not necessarily dependent upon anti-inflammatory properties.

Currently, it is unknown whether the neuroprotective effects of oestrogen treatments in EAE are directly mediated by binding oestrogen receptors on neurons or are indirectly mediated by binding oestrogen receptors on non-neuronal CNS cells. While neurons express oestrogen receptors and could be a target for oestrogen’s actions, glial cells (oligodendrocytes, astrocytes and microglia) also express oestrogen receptors [202]. Myelin/axonal interactions, as well as astrocytic support for neurons, each make it possible that oligodendrocytes or astrocytes, respectively, may be the targets for oestrogen’s protective effect on neurons and axons in vivo. Further, the neuroprotective effect of estrogens in vivo during EAE could also be mediated by reducing microglia activation since microglial activation can be deleterious for neurons.

**Treatment with ovarian hormones in MS**

Levels of oestrogens that are lower than those which occur during pregnancy, such as levels induced by doses in oral contraceptives or hormone replacement therapy, may or may not be high enough to be protective in MS. While some studies have attempted to simulate a situation of treatment with oral contraceptives in EAE mice and have shown an effect on disease [122,127], doses used in mice are not readily translatable to humans. In fact, the data in humans thus far has suggested that treatment with oral contraceptives is not likely to suppress MS. The incidence rate of MS onset in both former and current oral contraceptive users was not different from that in never-users [203]. It is not surprising that former use of oral contraceptives in healthy women would have no effect on subsequent risk to develop MS, since one would not anticipate that the effect of treatment on the immune system would be permanent. However, the fact that incidence rates for MS in current oral contraceptive pill users were not decreased, compared to never-users, suggests that the oestrogens in oral contraceptives are not of sufficient type or dose to ameliorate the immunopathogenesis of MS, even temporarily, during current use. This remains an unresolved issue as controversial results emerge with respect to the use of oral contraceptives and MS risk during current use [204,205]. Studies of hormone replacement therapy and effects on disease activity in rheumatoid arthritis can provide further clues with respect to which doses of oestrogens could potentially be protective in MS [206]. In a randomized placebo controlled trial of transdermal oestradiol in 200 postmenopausal RA patients, who continued other anti-rheumatic medications, it was found that those who achieved a serum oestradiol level > 100 pmol/L had significant improvements in articular index, pain scores, morning stiffness and sedimentation rates, while those with lower oestradiol levels did not demonstrate improvement [207]. There has been no consistent correlation between disease markers in MS or RA and hormone levels during the menstrual cycle in females. Together, these reports suggest that it is probable that a sustained level of a sufficient dose of an oestrogen will be necessary to ameliorate disease activity in MS and RA.

Since oestradiol is the major oestrogen of pregnancy and since an oestriol dose which yielded a pregnancy level in mice was protective in disease [129], oestradiol was administered in a prospective pilot clinical trial to women with MS, in an attempt to recapitulate the protective effect of pregnancy on disease [208]. A crossover study was used whereby patients were followed for 6 months pre-treatment to establish baseline disease activity which included cerebral MRI every month and neurologic exam every 3 months. The patients were then treated with oral oestradiol (8 mg/day) for 6 months and then observed for 6 months or more months in the post-treatment period. There were six RR patients and four SP patients who finished the 18 month study period. The RR MS subjects were then retreated with oral oestradiol and progesterone in a four month extension phase. Oestradiol treatment resulted in serum oestradiol levels which approximated levels observed in untreated healthy control women who were 6 months pregnant. Interestingly, a significant decrease in a prototypic in vivo Th1 response, the delayed type hypersensitivity response to the recall antigen tetanus, was observed at the end of the 6 month treatment period as compared to the pre-treatment period. When PBMCs were stimulated ex vivo, a favourable shift in cytokine profile (decreased TNFα, increased IL10 and IL5) was observed during treatment as compared to baseline [209]. On serial MRIs, the RR patients demonstrated an 80% reduction in gadolinium enhancing lesions within 3 months of treatment, compared to pre-treatment [208] and this
improvement in enhancing lesions correlated with the favourable shift in cytokine profiles [209]. Importantly, gadolinium enhancing disease activity gradually returned to baseline in the post treatment period and the favourable cytokine shift also returned to baseline. Further, in the 4 month extension phase of the study, both the decrease in brain enhancing lesions and the favourable immune shift, returned upon retreatment with oestril in combination with progesterone in the RR MS group. These latter data have important translational implications since progesterone treatment is needed in combination with oestrogen treatment to prevent uterine endometrial hyperplasia when oestrogens are administered for a year or more in duration. These results indicate that treatment with progesterone in combination with oestril did not neutralize the beneficial effect of oestriol treatment on these biomarkers of disease. A multi-centre, double-blind, placebo-controlled trial of oestriol treatment in RR MS is now ongoing in the USA. 

Now we will review, and attempt to reconcile, findings of oestrogen treatment in basic science with oestrogen treatment in clinical trials in other diseases, mostly neurodegenerative diseases. Despite very promising results in various in vitro and in vivo animal systems describing neuroprotective effects of oestrogen treatment (reviewed above), a large study of oestrogen replacement therapy in mild to moderate Alzheimer's disease, with subjects an average age of 75 years, yielded disappointing results with no significant effects on clinical outcomes [210]. It has been hypothesized that either the age of the subject population, or the stage of disease, may be critical in whether a neuroprotective effect of oestrogen treatment can be appreciated [211]. Adequate levels of oestrogen receptors, or associated intracellular cofactors, may no longer be optimally expressed in either hormonally senescent, or significantly diseased, brains. Indeed the effect of oestrogen treatment on the blood brain barrier has been shown to be quite different when comparing senescent versus younger rats [212]. Clinical reports also indicate differential effects of oestrogen treatment depending on age and disease status. Oestrogen replacement had no effect on cognition in elderly menopausal women [213], while it preserved cognition in younger women undergoing surgical hysterectomy [214,215]. In a large trial assessing the effects of oestrogen treatment in stroke, treatment had no effect on cognition in women with stroke who had cognitive impairment at baseline but treatment reduced the risk for cognitive decline in those with normal cognition at baseline [216]. Finally, an improvement in cognitive function was observed with oestriol treatment in early RRMS, but not in late SPMS [208]. A ‘healthy cell bias of oestrogen action’ has been hypothesized to explain the disparity between promising results of oestrogen treatment in animal models of neurodegenerative diseases versus disappointing results in oestrogen treatment in some neurodegenerative disease trials [217]. Efficacy of oestrogen treatment appears to depend critically upon its administration early, as a preventative therapy, before neurodegeneration has occurred [210]. Also, results may be more promising if there is not a prolonged period of hypoestrogenicity before treatment with oestrogens [199]. Plaques in coronary arteries, a biomarker for cardiovascular risk, were reduced when conjugated equine oestrogens were administered relatively early to women 50-59 who had undergone hysterectomy [218].

The question is then prompted regarding whether oestrogen treatment might also need to be instituted relatively early in autoimmune or neurodegenerative diseases. Together, these data warrant further study of treatments with oestrogens, in MS and other diseases, which consider the age and disease duration of the subjects.

In summary, there has been shown that there is a protective effect of relatively high doses of oestrogens (oestradiol and oestriol) within the late pregnancy range in the MS model, while a role for lower endogenous fluctuating levels of estrogens during the menstrual cycle are controversial. In addition, there is no evidence that progesterone treatment is protective in the MS model. Mechanisms underlying the protective effects of high dose oestrogens include both anti-inflammatory and neuroprotective properties. Whether treatment with supplemental oestrogens may be protective in women with MS is currently being investigated through clinical trials.

**Sex chromosome effects in autoimmune disease**

A non-mutually exclusive alternative to sex hormone-induced differences in autoimmune disease is a direct genetic effect on the immune system. That is, specific gene products, which are not induced by gonadal hormones but are expressed in a sexually dimorphic manner in the immune system, could induce sex-specific patterns of immune system development or function.

In male mammals, the Y-linked gene Sry is expressed in cells of the undifferentiated gonadal ridges to cause them to differentiate into Sertoli cells, which begins the differentiation of the testes [219]. Once the testes have formed, they secrete hormones distinct from those of the ovary and these hormonal differences generate sex differences in many non-gonadal tissues such as the external genitalia, immune system and central nervous system. Indeed, the effects of these hormones account for the majority of sex differences in non-gonadal tissues identified to date. However, there are other genetic differences between males and females arising from the difference in sex chromosome complement that could
also contribute to sex differences in phenotype [220,221]. There are other Y genes whose role in non-gonadal hormones has been little studied and there are also differences in X gene expression arising from the difference in X chromosome complement. As it has been much easier to study the effects of gonadal hormones than these possible direct effects of X and Y genes, the sexually differentiating effects of hormones are much better understood. The focus of this section will be on whether direct actions of X or Y genes on tissues may also be important in autoimmunity.

As gonadectomy gives only limited information about putative effects of genes on sex chromosomes, we turned to a mouse strain that had been used by investigators studying sexually dimorphic development [221-226]. In these mice, the testis-determining gene \textit{Sry} is ‘moved’ from the Y chromosome to an autosomal by successive deletion from the Y chromosome and introduction of an \textit{Sry} transgene onto an autosomal. Thus, the inheritance of genes causing testicular differentiation is separated from the Y chromosome, and the Y chromosome can be present or absent in phenotypic male (testis-bearing) mice and it can be present or absent in phenotypic female (ovary-bearing) mice. The Y chromosome deficient in the \textit{Sry} gene is denoted \textit{Y} and \textit{XY Sry} male mice carry the \textit{Sry} transgene. When this mouse is mated with an XX female, four progeny result: XX females, XY’ females, XXXsry males and XY Sry males.

In order to determine the role of genes on sex chromosomes on autoantigen specific immune responses, we backcrossed the outbred MF1Y \textit{Sry} mice onto the SJL strain. We chose the SJL strain because a sex bias had been clearly shown in the SJL, with female SJL mice more susceptible than males to EAE [60-62,77,227]. Further, autoantigen specific immune responses had been shown to differ between females and males immunized with either MBP or PLP, with greater levels of Th1 cytokines produced in draining lymph node cells (LNCs) of females as compared to males [61,79,80,227,228]. In order to address direct effects of sex chromosomes on immune responses, the immune responses would be examined in SJL mice which differed in the complement of sex chromosomes, while having the same gonadal type. Gonadal females (XX and XY’) were ovariectomized prior to immunization to remove an effect of adult circulating female hormones on immune responses. Immune responses were significantly higher in ovariectomized XY’ mice compared to ovariectomized XX mice. These included increased levels of IFN\textsubscript{\gamma}, TNF\alpha and IL-10 in supernatants of autoantigen stimulated immune cells. Further, when gonadal male mice were castrated prior to immunization, immune responses were significantly higher in castrated XY Sry mice as compared to castrated XXXsry mice. While these data are consistent with an immunostimulatory role for a gene on the X chromosome [39], these findings cannot distinguish from an immunosuppressive effect of a gene on the Y chromosome [229].

The finding that the XY’ sex chromosome complement, compared to the XX, was relatively more stimulatory with respect to cytokine responses (IFN\textsubscript{\gamma}, TNF\alpha, IL10) during autoantigen specific stimulation supported the concept of direct effects of sex chromosomes on autoimmune, but the precise role in autoimmune disease remained unknown. IFN\textsubscript{\gamma} and TNF\alpha may have either disease promoting or disease protective effects depending on the dose and timing of their production, while IL10 is generally considered to be protective in EAE. In addition, there are numerous other cytokines, chemokines, adhesion molecules and co-stimulatory factors that play a role in EAE pathogenesis and they, too, could theoretically be affected by sex chromosome complement. Thus, to directly assess the role of sex chromosome complement in disease, EAE was induced in mice with the informative sex chromosome complements. Specifically, both females and males were gonadectomized to remove any intercurrent effects of sex hormones which might mask effects of sex chromosomes [230]. SJL castrated male mice that were either XXSry or XY Sry, had active EAE induced with proteolipid protein peptide (PLP) 139-151 peptide. Clinical disease course was significantly more severe in XXXsry mice, as compared to XY Sry mice. This significant difference in disease severity also occurred when comparing ovariectomized female XX versus XY’ mice. Further, in adoptive EAE, CNS pathology revealed higher levels of inflammation in mice that had received autoantigen specific cells derived from XX mice compared to those from XY’ mice. Together, these data showed that the XX sex chromosome complement, as compared to the XY’, was associated with a greater ability to induce EAE [231].

As it had been previously shown that no sex bias existed in EAE in the C57BL/6 strain of mice [70-72], it was then ascertained whether an effect of sex chromosomes could be found in this strain. Thus, the \textit{Sry} deficient Y chromosome from the original outbred MF1 mouse [232] was backcrossed onto the C57BL/6 strain. Both females and males were gonadectomized in order to remove any effects of sex hormones which might mask the effects of sex chromosomes. C57BL/6 castrated male mice that were either XXSry or XY Sry had active EAE induced with (MOG) 35-55 peptide. In contrast to results in the SJL, clinical disease courses were no different when comparing XXSry mice with XY Sry mice [231]. There was also no difference in disease when comparing ovariectomized female XX versus XY’ mice. Together, these data indicated that, when a
strain was used that was characterized by a female to male difference in EAE (the SJL), a sex chromosome effect was present. In contrast, when a strain was used that is not characterized by a female to male difference in EAE (the C57BL/6), a sex chromosome effect was not present. The presence of a sex chromosome effect in one strain, but not another, revealed an interaction between sex chromosome complement and genetic background. Notably, effects of sex hormones in EAE have also previously been shown to be dependent on genetic background [231] and some autosomal gene linkages to susceptibility to MS have been identified in one gender but not the other [73]. Thus, in the outbred human population, the genetic background of some, but not all, individuals may be permissive to sex chromosome or sex hormone effects. Notably, as overall there is a sex difference in many autoimmune diseases in humans, we hypothesize that relatively permissive genetic backgrounds are likely to be prevalent, not rare, in occurrence.

In light of the fact that lupus in humans is characterized by a 9:1 female preponderance and since it had previously shown that pristane induced lupus in SJL mice was characterized by greater susceptibility in females as compared to males [233], it was then determined whether the effect of sex chromosome complement observed in SJL mice with EAE was unique to this disease or was more pervasive across autoimmune diseases. Thus, the role of sex chromosome complement in pristane induced lupus was investigated. Ovariectomized female XX and XY Sry SJL mice and castrated male XX*Sry and XY*Sry mice were injected with pristane and monitored daily for signs of disease. By 26 weeks only 30.8% of XX mice had survived, 68.4% of XY mice had survived. This significantly greater disease severity in XX mice also occurred when comparing castrated male XX*Sry mice with XY*Sry. Kidney pathology and levels of anti-dsDNA antibodies also revealed more severe disease in XX as compared to XY mice [231].

Together, data using the informative Sry transgenic mice indicated that the XX sex chromosome complement was disease promoting as compared to the XY complement. It remains to be determined whether this effect is due to: (1) gene(s) unique to the Y chromosome; (2) a higher dose of X genes which escape X-inactivation in XX mice; or (3) paternal imprinting of X genes which are present in XX, but not XY, mice [221]. Consistent with a potential X dosage effect in our lupus model, XXY men and XX women both have a similar high risk of developing lupus, while the incidence of lupus in XO females is very low [234,235]. Since these sex chromosome differences in humans are confounded by differences in sex hormones during both development and adulthood, it is difficult to distinguish between a sex chromosome effect versus a sex hormone effect in humans.

Conclusions

The study of sex differences in autoimmune disease includes: (1) research addressing female versus male differences in a given autoimmune disease; and (2) research focused on a major disease modifier which is inherent to being one sex. In autoimmune diseases, there are two major clinical observations related to sex: first, females are more susceptible than males; and, second, pregnancy reduces relapses in females. Both of these observations can be pursued with respect to basic mechanism and translational potential.

With regard to the clinical observation that females are more susceptible than males, the state of being female indeed confers more susceptibility risk to develop autoimmune disease than any gene or environmental factor identified to date. Basic research indicates a protective role for high levels of androgens in young males, with little role for fluctuating levels of ovarian hormones in females. Thus clinical trials of treatment with androgens in autoimmune disease are warranted. Further, a role for sex hormones is not mutually exclusive of a role for sex chromosomes. Indeed, the XX sex chromosome complement has been shown to be disease promoting as compared to XY. This sex chromosome effect is true in autoimmune disease models that are distinct in immunopathogenesis, including both cell mediated and antibody mediated diseases. The precise gene on X or Y remains to be determined.

With regard to the clinical observation that late pregnancy in females with MS is associated with an 80% reduction in relapses, this reduction is more dramatic than any of the first line drugs currently available to treat MS which reduce relapses by 30%-50%. A protective role for high levels of estrogens during late pregnancy has been shown in animal models. This is true for cell mediated, but not antibody mediated, diseases. Thus, clinical trials of treatment with pregnancy level estrogens in cell mediated autoimmune disease are warranted.

Thus, the study of clinically relevant sex differences, if understood at the basic science level, can lead to new treatments for a variety of autoimmune diseases.

Glossary

25’ timed walk = a measure of gait speed used as part of the MS Functional Composite Measure. The 25 foot timed walk is a mobility and leg function performance test in which MS patients are timed to walk 25 ft. Those patients unable to complete the 25 ft walk, need assistance or use a wheel chair, are noted as such.
Active EAE = EAE induced directly by immunization with an emulsion of adjuvant and stimulatory protein (autoantigen). This approach enables the study of disease inducer and effector phases of experimental demyelinating disease.

Adoptive EAE = CD4 T lymphocytes specific for the autoantigen are transferred from an immunized donor mouse to a naïve recipient mouse, with disease then occurring in the recipient mouse. This method of EAE allows for the separation of the induction and effector phases of the disease.

Allograft = a transplant of tissue, cells, or organs from a genetically non-identical source of the same species.

Aromatase = an enzyme of the cytochrome P450 superfamily, which functions to aromatize androgens to produce oestrogens.

Diffusion-weighted imaging = a type of MRI in which in vivo images of biological tissue are weighted with the microstructural characteristics of water diffusion within the tissue.

Gadolinium enhancing lesions = a delineated area of increased MR signal intensity on T1-weighted spin-echo images, compared to normal-appearing surrounding brain tissue following intravenous injection of a gadolinium chelate.

Expanded Disability Status Scale (EDSS) = a method for quantifying disability in MS patients, in which neurologists assess eight functional systems: pyramidal, cerebellar, brainstem, sensory, bowel and bladder, visual, cerebral and other.

Hashimoto's thyroiditis = a type of autoimmune thyroid disease in which the immune system attacks and destroys the thyroid gland, causing a dysfunctional production of thyroid hormones.

Lymph node cells (LNCs) = cells cultured from the lymph nodes, organs belonging to the lymphatic system and found throughout the body. The lymph nodes house several immune cell types including B cells, T cells, plasma cells, macrophages, reticular cells and white blood cells.

Nine-hole peg task = the nine-hole peg task is used to measure fine manual dexterity of the right and left hands in MS patients.

Non-obese diabetic (NOD) mice = a mouse strain susceptible to spontaneous development of autoimmune insulin dependent diabetes mellitus.

Normal appearing white matter (NAWM) = myelinated area of the CNS that appears intact and healthy via MRI but that may contain abnormalities and lesions.

Oophorectomy = another term for ovariecctomy, the surgical removal of the female reproductive organs, ovaries.

Paced Auditory Serial Addition Task (PASAT) = a cognitive task given to MS patients to measure auditory information processing speed and flexibility, as well as calculation ability.

Primary biliary cirrhosis = an autoimmune disease of the liver, in which the small bile ducts are slowly and progressively destroyed. This causes bile accumulation, which damages surrounding tissue and can lead to scarring, fibrosis, cirrhosis and eventual liver failure.

Pristane = a natural saturated alkaline found primarily in shark liver oil. Pristane is used as an immunologic adjuvant to induce systemic lupus erythematosus (SLE).

PD-1 = programmed death marker 1.

Sedimentation rate = also referred to as erythrocyte sedimentation rate (ESR), the speed at which red blood cells (erythrocytes) fall to the bottom of a fine glass tube filled with a RA patient’s blood. A faster ESR indicates a higher level of inflammation, and aids in determining the severity of the condition.

Sertoli cells = a type of supporting cell found in the seminiferous tubules within the testes, important for maturation of spermatocytes.

Sjogren's syndrome = a chronic autoimmune disease in which white blood cells attack systemic moisture producing glands, such as the tear duct and salivation glands.

T2 lesion = a hyperintense region in an MRI scan, where normal appearing white matter would be dark.

T2-weighted imaging = a type of MRI contrast, in which water concentration affects image intensity. As an example, oedema would appear as a hyperintense spot on the MRI scan and white matter would appear dark in this contrast type.

Uterine endometrial hyperplasia = a condition in which the endometrium lining of the uterus excessively proliferates.

Wallerian degeneration = a process that results from the cutting or crushing of a nerve fibre in which the axon degenerates after it is detached from its neuronal cell body.

Abbreviations

CNS: central nervous system; DHT: dihydrotestosterone; EAE: experimental autoimmune encephalomyelitis (a mouse model of MS); ER: oestrogen receptor; HPA: hypothalamic-pituitary axis; IFN: interferon; IL: interleukin; MBP: myelin basic protein; MOG: myelin oligodendrocyte protein; MRI: magnetic resonance imaging; MS: multiple sclerosis; NAWN: normal appearing white matter; PLP: proteolipid protein; PBMC: peripheral blood lymphocytes; RA: rheumatoid arthritis; RR: relapsing remitting; SP: secondary progression; TNF: tumour necrosis factor; Th1: T helper 1.

Acknowledgements

This work was supported by grants K24NS062117, R21NS071210 from the NIH, RG4364 and RG4033 from the National Multiple Sclerosis Society as well as the Skirball Foundation, the Hilton Foundation, and the Sherak Family Foundation.

Authors’ contributions

RRV reviewed the literature and wrote the review.
Author’s information

RRV is a Professor of Neurology and Director of the UCLA Multiple Sclerosis Program. Her career has focused principally on basic science and clinical trials in multiple sclerosis.

Competing interests

UCLA holds a use patent for oestradiol treatment in MS of which Dr Voskuhl is an inventor. Dr Voskuhl is a consultant for Adeona Pharmaceuticals receiving a maximum of $10,000 per year.

Received: 29 September 2010 Accepted: 4 January 2011

Published: 4 January 2011

References

1. Calabresi PA, Stone LA, Bash ON, Frank JA, McFarland HF: Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997, 48(5):1446-1448.
2. Ge Y, Grossman RI, Udupa JK, Fulton J, Constantinescu CS, Gonzales-Scarno F, Babb JS, Mannon LJ, Kolson DL, Cohen JA: Glutamatergic (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology, 2000, 54(4):813-817.
3. Li DK, Pany DW: Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta-1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 1999, 46(2):197-206.
4. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, et al: Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group [see comments]. Ann Neurol 1998, 43(1):79-87.
5. Zhao GJ, Koopmans RA, Li DK, Bedell L, Pany DW: Effect of interferon beta-1b in MS: assessment of annual accumulation of PD/T2 activity on MRI. UBC MS/MRI Analysis Group and the MS Study Group. Neurology 2000, 54(1):200-206.
6. Stevenson VL, Miller DH, Leahy SM, Rovaris M, Barkhof F, Brochet B, Dousset V, Filippi M, Hintzen R, Montalban X, et al: One year follow-up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2000, 68(6):713-718.
7. Rice GP, Filippi M, Comi G: Cladrabine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladrabine MRI Study Group, Neurology 2000, 54(5):1145-1155.
8. Martin R, Ferraro J, Kappos L, McDonald WI: Multiple sclerosis: in vivo effects of interferon beta-1a on immunosuppressive cytokines in patients with multiple sclerosis. J Clin Invest 2000, 105(7):967-976.
9. Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, Zhang JZ: In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis [published erratum appears in Neurology 1998 Jul 51 (1): 332]. Neurology, 1998, 50(5):1294-1300.
10. Bode PJ, Schmied MC, Cook SL, Krieger JJ, Hafer DA: Glatiramer acetate (Copaxone) induces degenerate, TH2-polarized immune responses in patients with multiple sclerosis. J Clin Immunol 2000, 20(5):184-191.
11. Voskuhl RB, Bernard RH, Raskind MA, Chaudhry S, Somers T, Weil D, Zhang X, Bland HM, Miller DH: Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings. J Neuroimaging 2001, 11(2):129-136.
12. Legh R, Benedict RH, Selmaj K,Israeli B, Raskind MA, Hubert W, Zeng Y, Zang JZ: Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000, 54(8):1689-1691.
13. Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, Martelli V, Grossman RI, Scotti G, Comi G, et al: Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003, 126(Pt 2):433-437.
14. Ge Y, Grossman RI, Udupa JK, Wei L, Mannon LJ, Polansky M, Kolson DL: Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology 2000, 214(3):665-670.
15. Polman CH, O, J, Le Page E, Jones J, Trip SA, Deans J, Seaman S, Miller DH, Thompson AJ: Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 1996, 2006-2009.
16. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L: Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999, 53(8):1698-1704.
17. Stevenson VL, Leary SM, Losseff NA, Parker GJ, Barker GI, Husmani Y, Miller DH, Thompson AJ: Spinal cord atrophy and disability in MS: a longitudinal study. Neurology. 1998, 51(1):234-238.
18. Catalaa I, De Stefano N, Narayanan S, Matthews PM, Arnold DL: Imaging of axonal damage in multiple sclerosis: spatial distribution of magnetic resonance imaging lesions. Ann Neurol 1997, 41(3):385-391.
19. Gasperi K, Honfield MA, Thorpe JW, Kidd D, Barker GI, Tofts PS, MacManus DG, Thompson AJ, Miller DH, McDonald WI: Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: relationship to clinical parameters. J Magn Reson Imaging 1996, 6(4):580-584.
20. Filippi M, Iannucci G, Cercignani M, Assunta RM, Pratesi A, Comi G: A quantitative study of water diffusion in multiple sclerosis lesions and normal-appearing white matter using echo-planar imaging. Arch Neurol 2002, 59(7):1017-1021.
21. Filippi M, Inglese M, Rovaris M, Somers TM, Horstfeld P, Iannucci PG, Colombo B, Comi G: Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study [In Process Citation]. Neurology 2000, 55(7):940-946.
22. De Stefano N, Narayanan S, Matthews PM, Francis GS, Antel JP, Arnold DL: In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999, 122(PT 10):1933-1939.
23. Catalaa I, Grossman RI, Kolson DL, Udupa JK, Nyl LG, Wei L, Zhang X, Zeng JZ: Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: relationship to clinical parameters. J Magn Reson Imaging 1996, 6(4):580-584.
24. Filippi M, Iannucci G, Cercignani M, Assunta RM, Pratesi A, Comi G: A quantitative study of water diffusion in multiple sclerosis lesions and normal-appearing white matter using echo-planar imaging. Arch Neurol 2002, 59(7):1017-1021.
25. Catalaa I, Udupa JK, Wei L, Mannon LJ, Kolson DL, Grossman RI, Wei L, McGowan JC, Polansky M, Grossman RI: MRI imaging quantification of gray matter involvement in multiple sclerosis and its correlation with disability measures and neurocognitive testing. J Neuroimag 1999, 20(8):1613-1618.
26. Baloh R, Benedict RH, Raskind MA, Jacobs L: Regional brain atrophy is associated with physical disability in multiple sclerosis: semiquantitative magnetic resonance imaging and relationship to clinical findings. J Neuroimaging 2001, 11(2):129-136.
27. Gasperi K, Honfield MA, Thorpe JW, Kidd D, Barker GI, Tofts PS, MacManus DG, Thompson AJ, Miller DH, McDonald WI: Macroscopic and microscopic assessments of disease burden by MRI in multiple sclerosis: relationship to clinical parameters. J Magn Reson Imaging 1996, 6(4):580-584.
28. Filippi M, Iannucci G, Cercignani M, Assunta RM, Pratesi A, Comi G: A quantitative study of water diffusion in multiple sclerosis lesions and normal-appearing white matter using echo-planar imaging. Arch Neurol 2002, 59(7):1017-1021.
29. Filippi M, Inglese M, Rovaris M, Somers TM, Horstfeld P, Iannucci PG, Colombo B, Comi G: Magnetization transfer imaging to monitor the evolution of MS: a 1-year follow-up study [In Process Citation]. Neurology 2000, 55(7):940-946.
30. De Stefano N, Narayanan S, Matthews PM, Francis GS, Antel JP, Arnold DL: In vivo evidence for axonal dysfunction remote from focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999, 122(PT 10):1933-1939.
31. Catalaa I, Grossman RI, Kolson DL, Udupa JK, Nyl LG, Wei L, Zhang X, Polansky M, Mannon LJ, McGowan JC: Multiple sclerosis: magnetization transfer histogram analysis of segmented normal-appearing white matter. Radiology 2000, 216(2):351-355.
32. Santos AC, Narayanan S, de Stefano N, Tartaqlia MC, Francis SJ, Arnaoutakis R, Caramanos Z, Antel JP, Pike GB, Arnold DL: Magnetization transfer can predict clinical evolution in patients with multiple sclerosis. J Neuroimaging 2002, 249(6):662-668.
33. Peterson JW, Bo L, Mark S, Chang A, Trapp BD: Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 2001, 50(3):389-400.
34. Bo L, Vederer CA, Nyland H, Trapp BD, Mark S: Subpial demyelination in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp Neuros 2003, 62(7):723-732.
The neuroendocrine axis in patients with multiple sclerosis.

Gender-dependent IL-12 secretion by APC is regulated by IL-10.

Decreased bioavailable testosterone in aging normal and impotent men.

Characterization of type 1 and type 2 cytokine production profile in healthy older men.

Increased neurotrophic factor production in multiple sclerosis patients suppresses relapses in experimental autoimmune encephalomyelitis: a preliminary outcome measure.

Androgens alter the T-helper 1-type immunity to trophoblast in women with recurrent spontaneous abortion. [see comments].

The role of prolactin to increase IL10 production.

The effects of aging on normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate.

Increased autoantigen-specific T lymphocyte response.

The effects of aging on normal men on bioavailable testosterone and luteinizing hormone secretion: response to clomiphene citrate.

The role of prolactin to increase IL10 production.

The role of prolactin to increase IL10 production.

Characterization of MRI response to treatment with Adrenocorticotropin, glucocorticoid, and androgen secretion in patients with AIDS-related complex.

Characterization of MRI response to treatment with Adrenocorticotropin, glucocorticoid, and androgen secretion in patients with AIDS-related complex.

Characterization of MRI response to treatment with Adrenocorticotropin, glucocorticoid, and androgen secretion in patients with AIDS-related complex.
evidence for a suppressive pregnancy-related serum factor. J Immunol 2002, 169(2):1084-1091.

Voskuhl RR, Palazynsky K: Sex hormones and experimental autoimmune encephalomyelitis: implications for multiple sclerosis. The Neuroscientist 2001, 7(3):258-270.

Bebo BF Jr, Fyfe-Johnson A, Adlard K, Beam AG, Vandenbark AA, Offner H: Low-dose estrogen therapy ameliorates experimental autoimmune encephalomyelitis in two different inbred mouse strains. J Immunol 2001, 166:2080-2089.

Ito A, Bebo BF Jr, Matejuk A, Zamora A, Silverman M, Fyfe-Johnson A, Offner H: Estrogen treatment down-regulates TNF-alpha production and reduces the severity of experimental autoimmune encephalomyelitis in cytokine knockout mice. J Immunol 2001, 167(1):542-552.

Liu HY, Buenafe AC, Matejuk A, Ito A, Zamora A, Dwyer J, Vandenbark AA, Offner H: Estrogen inhibition of EAE involves effects on dendritic cell function. J Neurosci Res 2003, 70(2):238-248.

Matejuk A, Adlard K, Zamora A, Silverman M, Vandenbark AA, Offner H: 17beta-estradiol inhibits cytokine, chemokine and chemokine receptor mRNA expression in the central nervous system of female mice with experimental autoimmune encephalomyelitis. J Neurosci Res 2001, 63(6):529-542.

Polanczyk M, Zamora A, Subramanian S, Matejuk A, Hess DL, Blankenhorn EP, Teuscher C, Vandenbark AA, Offner H: The protective effect of 17beta-estradiol on experimental autoimmune encephalomyelitis is mediated through estrogen receptor-alpha. Am J Pathol 2003, 163(4):1599-1605.

Subramanian S, Matejuk A, Zamora A, Vandenbark AA, Offner H: Oral feeding with ethinyl estradiol suppresses and treats experimental autoimmune encephalomyelitis in 2L mice and inhibits the recruitment of inflammatory cells into the central nervous system. J Immunol 2003, 170(3):1548-1555.

Jansson L, Olsson T, Holmdahl R: Estrogen induces a potent suppression of experimental autoimmune encephalomyelitis and collagen-induced arthritis in mice. J Neuroimmunol 1994, 53(2):203-207.

Kim S, Liwa SM, Dalal MA, Verity MA, Voskuhl RR: Estradiol ameliorates autoimmune demyelinating disease: implications for multiple sclerosis. Neurology 1999, 52(6):1230-1238.

Liu HB, Loo KK, Palazynsky K, Ashouri J, Lubahn DB, Voskuhl RR: Estrogen receptor alpha mediates estrogen's immune protection in autoimmune disease. J Immunol 2003, 171(2):6936-6940.

Palazynsky KM, Liu H, Loo KK, Voskuhl RR: Estradiol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neuroimmunol 2004, 149(1-2):84-89.

Jansson L, Holmdahl R: Oestrogen-induced suppression of collagen arthritis. I: Collagen arthritis does not affect the course of arthritis but enhances the oestrogen-mediated therapeutic effect. J Reproductive Immunol 1989, 14(2):141-150.

Jansson L, Holmdahl R: Oestrogen modulates experimental autoimmune encephalomyelitis and interleukin-17 production via programmed death 1. Immunology 2009, 128(3):329-335.

Zhang QH, Hu YZ, Cao J, Zhong YQ, Zhao YF, Mei QB: Estrogen influences the differentiation, maturation and function of dendritic cells in rats with experimental autoimmune encephalomyelitis. Acta Pharmacol Sin 2004, 25(4):508-513.

Xiao BG, Liu X, Link H: Antigen-specific T cell functions are suppressed over the estrogen-dendritic cell-Indoleamine 2,3-dioxxygenase axis. Steroids 2004, 70(2):129-135.

Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C, Mellor AL: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 1998, 281(5380):1191-1193.

Mellor AL, Munn DH: IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 2004, 4(10):762-774.

Polanczyk MJ, Canzon BD, Subramanian S, Mertouilis M, Vandenbark AA, Zaggier SF, Offner H: Cutting edge: estrogen drives expansion of the CD4+CD25+ regulatory T cell compartment. J Immunol 2004, 173(4):2227-2230.

Matejuk A, Bakke AC, Hopke C, Dwyer J, Vandenbark AA, Offner H: Estrogen treatment induces a novel population of regulatory cells, which suppresses experimental autoimmune encephalomyelitis. J Neurosci Res 2004, 77(1):119-126.

Jansson L. Estrogen-induced suppression of collagen arthritis II: Estrogen-induced suppression of collagen arthritis. Antigen-specific T cell functions are suppressed over the estrogen-dendritic cell-Indoleamine 2,3-dioxxygenase axis. Steroids 2004, 70(2):129-135.

Brinton RD: Cellular and molecular mechanisms of estrogen regulation of memory function and neuroprotection against Alzheimer’s disease: recent insights and remaining challenges. Learn Mem 2003, 10(3):121-133.

Garcia-Segura LM, Azzarito J, DonCarlos LL: Neuroprotection by estradiol. Prog Neurobiol 2001, 63(1):29-60.

Dhawan V, Dubal DB, Wilson ME, Bhat SW, Bottrill M, Minireview: neuroprotective effects of estrogen-new insights into mechanisms of action. Endocrinology 2001, 142(3):969-973.

Srivinchai EA, Wingrave JHM, Matzele DD, Ray SK, Bank NL: Estrogen as a neuroprotective agent in the treatment of spinal cord injury. Ann N Y Acad Sci 2003, 993:125-133, discussion 159-160.

Goodman Y, Bruce AJ, Cheng B, Mattson NP: Estrogens attenuate and corticosterone exacerbates excitotoxicity, oxidative injury, and amyloid beta-peptide toxicity in hippocampal neurons. J Neurochem 1996, 66(5):1836-1844.

Harms C, Lautenschlager M, Bergk A, Kathanov J, Freyer D, Kapinya K, Herwig U, Megow D, Dimagi U, Weber JR, et al: Differential mechanisms
of neuroprotection by 17 beta-estradiol in apoptotic versus necrotic neurodegeneration. J Neurosci 2001, 21(8):2600-2609.

162. Behl C, Skutella T, Lezoualch F, Post A, Widmann M, Newton CJ, Holshaer F: Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Cell Endocrinol 1997, 138(3):265-271.

163. Behl C, Widmann M, Trapp T, Holshaer F: 17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochim Biophys Acta 1995, 126(2):473-482.

164. Zhao L, Wu TW, Brinton RD: Role of glial cells in neurodegeneration. J Neurosci 2000, 21(10):3923-3927.

165. Sribnick EA, Ray SK, Nowak MW, Li L, Banik NL: Estradiol attenuates oxidative stress-induced apoptosis in C6 glial cells. J Neurosci 2003, 23(36):8604-8609.

166. Bruce-Keller AJ, Keeling JL, Keller JW, Hugan FF, Camondola S, Mattson MP: Estrogen receptors alpha and beta contribute to neuroprotection and increased Bcl-2 expression in primary hippocampal neurons. J Neurosci 2004, 24(10):2843-2854.

167. Vegeto E, Bonincontro C, Polillo G, Sala A, Viappiani S, Nardi F, Brusadelli A, Viviani B, Ciana P, Maggi A: Estradiol prevents the lipopolysaccharide-induced inflammatory response in microglia. J Neurosci 2001, 21(6):1809-1818.

168. Drew PD, Chavis JA: Female sex steroids: effects upon microglial cell activation. J Neuroimmunol 2000, 111(2-3):77-85.

169. Garcia-Segura LM, Naftolin F, Hutson JB, Azcoitia I, Chowen J: Role of astroglia in estrogen regulation of synaptic plasticity and brain repair. J Neurobiol 1999, 40(4):574-584.

170. Azzotita I, Sierra A, Garcia-Segura LM: Localization of estrogen receptor beta-immunoactivity in astrocytes of the adult rat brain. Glia 1999, 26(3):260-267.

171. Sur P, Sribnick EA, Wingrave JM, Nowak MW, Ray SK, Banik NL: Estrone attenuates oxidative stress-induced apoptosis in C6 glial cells. Brain Res 2003, 971(2):178-188.

172. Takao T, Flint N, Lee L, Ying X, Merritt J, Chandross KJ: 17-beta-estradiol protects oligodendrocytes from cytotoxicity induced cell death. J Neurochem 2004, 89(3):660-673.

173. Cantarella G, Risuglia N, Lombardo G, Lempereur L, Nicoletti F, Memo M, Bernardini R: Protective effects of estradiol on TRAIL-induced apoptosis in human oligodendrocytic cell line: evidence for multiple sites of interactions. Cell Death Differ 2004, 11:503-311.

174. Zhang Z, Cheng M, Mullins C, Williamson M, Bessert D, Skoff R: Comparison of in vivo and in vitro subcellular localization of estrogen receptors alpha and beta in oligodendrocytes. J Neurochem 2004, 89(3):674-684.

175. Yune TY, Kim SJ, Lee SM, Lee YK, Oh YJ, Kim YC, Markelos GJ, Oh TH: Systemic administration of 17-beta-estradiol reduces apoptotic cell death, and improves functional recovery following traumatic spinal cord injury in rats. J Neurotrauma 2004, 21(3):293-306.

176. Rau SW, Dubal DB, Bottoni M, Gehold LM, Wise PM: Estradiol attenuates programmed cell death after stroke-like injury. J Neurosci 2003, 23(36):11420-11426.

177. Sierra A, Azcoitia I, Garcia-Segura L: Endogenous estrogen formation is neuroprotective in model of cerebellar ataxia. Endocrinology 2003, 211(4):43-51.

178. Matsuda J, Vanier MT, Sato Y, Suzuki K: Dramatic phenotypic improvement during pregnancy in a genetic leukodystrophy: estrogen appears to be a critical factor. Hum Mol Genet 2001, 10(23):2707-2715.

179. Leranth C, Roth RH, Elsworth JD, Naftolin F, Horvath TL, Redmond DE Jr: Estradiol increases dendritic spine density by reducing GABA neurotransmission in hippocampal neurons. J Neurosci 1998, 18(7):2530-2539.

180. Woolley CS: Effects of estrogen in the CNS. Curr Opin Neurobiol 1999, 9(3):349-354.

181. Yankova M, Hart SA, Woolley CS: Estrogen increases synaptic connectivity between single presynaptic inputs and multiple postsynaptic CA1 pyramidal cells: a serial electron-microscopic study. Proc Natl Acad Sci USA 2001, 98(6):3525-3530.

182. Rudick CN, Woolley CS: Estrogen regulates fundamental inhibition of hippocampal CA1 pyramidal cells in the adult female rat. J Neurosci 2001, 21(17):6532-6543.

183. Sandstrom NJ, Williams CL: Memory retention is modulated by acute estradiol and progesterone replacement. Behav Neurosci 2001, 115(2):384-393.

184. Weiss DJ, Gurpide E: Non-genomic effects of estrogens and antiestrogens. J Steroid Biochem 1988, 31(4B):671-676.

185. Kuiper GG, Shughrue PJ, Merchenthaler I, Gustafson JA: The estrogen receptor beta subtype: a novel mediator of estrogen action in neuroendocrine systems. Front Neuroendocrinol 1998, 19(4):253-286.

186. Enmark E, Gustafsson JA: Oestrogen receptors - an overview. J Intern Med 1999, 246(2):133-138.

187. Kuiper GG, Carlson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafson JA: Comparison of the ligand binding specificity and transactivation to tissue distribution of estrogen receptors alpha and beta. Endocr Rev 1999, 20(2):246-283.

188. Sribnick EA, Ray SK, Nowak MW, Banik NL: Estradiol prevents the lipopolysaccharide-induced inflammatory response in microglia. J Neurosci 2001, 21(6):1809-1818.

189. Garidou L, Laffont S, Douin-Echinard V, Coureau C, Krust A, Chambon P, Elloso MM, Phiel K, Henderson RA, Harris HA, Adelman SJ: Differential ligand activation of estrogen receptors ERalpha and ERbeta is mediated protection against brain injury. Proc Natl Acad Sci USA 2002, 1010(1-2):110-115.

190. Enmark E, Carlsson B, Grandien K, Enmark E, Petterson K, Wainer M, Gustafson JA: Mechanisms of estrogen action. Physiol Rev 2001, 81(4):1533-1565.

191. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafson J, Kushner PJ, Scanlan TS: Differential ligand activation of estrogen receptors ESR1 and ESR2 at AP1 sites. Science 1997, 277(5331):1508-1510.

192. Shang T, Brown M: Molecular determinants for the tissue specificity of SERMs. Science 2002, 295(5564):2465-2468.

193. Ericsson MC, Ohlsson C, Gustafsson JA, Carlsten H: Role of oestrogen receptors alpha and beta in immune organ development and in oestrogen-mediated effects on thymus. Immunology 2001, 103(1):17-25.

194. Igashhi H, Kouro T, Yokota T, Comp PC, Kincade PW: Age and stage dependency of estrogen receptor expression by lymphocyte precursors. Proc Natl Acad Sci USA 2001, 98(26):15131-15136.

195. Harrington WR, Sheng S, Barnett DH, Petz LN, Katzenellenbogen JA, Katzenellenbogen BS: Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transcription or transrepression. Mol Cell Endocrinol 2003, 206(1-2):113-22.

196. Ellsoo MM, Phiel K, Henderson RA, Harris HA, Adelman SJ: Suppression of experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands. J Endocrinol 2005, 185(2):243-252.

197. Gendreau JD, Laffont S, Krust A, Catania MV, Sortino MA: Differential expression of estrogen receptors in experimental autoimmune encephalomyelitis using estrogen receptor-selective ligands. J Neuroimmunol 2005, 173(4):2435-2442.

198. Suzuki S, Brawn CM, Deia Cruz CD, Yang E, Bridwell DA, Wise PM: Timing of estrogen therapy after ovarectomy dictates the efficacy of its neuroprotective and anti-inflammatory actions. Proc Natl Acad Sci USA 2007, 104(14):6013-6018.

199. Du S, Sandoval F, Trinh P, Voskuhl RR: Additive effects of combination treatment with anti-inflammatory and neuroprotective agents in experimental autoimmune encephalomyelitis. J Neuroimmunol 2010, 219(1-2):64-74.

200. Treanor-Woodruff S, Voskuhl RR: Neuroprotective and anti-inflammatory effects of estrogen receptor ligand treatment in mice. J Neuro Sci 2009, 286(1-2):81-85.

201. Catania MV, Sortino MA: Differential expression of estrogen receptors in experimental autoimmune encephalomyelitis. J Neuroimmunol 2005, 173(4):2435-2442.
205. Hayman MA, Hohol MJ, Olek MJ, Spiegelman D, Aschner A: Oral contraceptives and the incidence of multiple sclerosis. Neurology 2000, 55(6):848-854.

206. Da Silva JA, Hall GM: The effects of gender and sex hormones on outcome in rheumatoid arthritis. Baillieres Clin Rheumatol 1992, 6(1):196-219.

207. Hall GM, Daniels M, Huskinson EC, Spector TD: A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis. Ann Rheum Dis 1994, 53(2):112-116.

208. Scicote NL, Liva SM, Lutich R, Pfeiffer P, Bouvier S, Odessa S, Wu TC, Voskuhl RR: Treatment of multiple sclerosis with the pregnancy hormone estron. Ann Neurol 2002, 52(4):421-428.

209. Soldan SS, Retuerto AJ, Scicote NL, Voskuhl RR: Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estron. J Immunol 2003, 171(11):6267-6274.

210. Mulnard RA, Cotman CW, Kavas C, van Dyck CH, Sano M, Doody R, Koss E, Pfeiffer E, Jin S, Garnot A, et al: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study (see comments). JAMA 2000, 283(8):1007-1015.

211. Mulnard RA, Corrada MM, Kavas CH: Estrogen replacement therapy, Alzheimer's disease, and mild cognitive impairment. Curr Neurol Neurosci Rep 2004, 5(10):369-375.

212. Bake S, Sohrabi F: 17beta-estradiol differentially regulates blood-brain barrier permeability in young and aging female rats. Endocrinology 2004, 145(12):5471-5475.

213. Binder EF, Schechtman KB, Birge SJ, Williams DB, Kohrt WM: Effects of hormone replacement therapy on cognitive performance in elderly women. Menopause 2001, 38(2):137-146.

214. Shervin EB: Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology 1988, 13(3):345-357.

215. Verghese J, Kuslansky G, Katz MJ, Slivinski M, Crystal HA, Buschke H, Lipton RB: Cognitive performance in surgically menopausal women on estrogen. Neurology 2003, 55(2):872-874.

216. Viscelli CM, Brass LM, Kernan WN, Sarrel PM, Suzuki S, Horwitz R: Estrogen therapy and risk of cognitive decline: results from the Women's Estrogen for Stroke Trial (WEST). Am J Obstet Gynecol 2005, 192(2):387-393.

217. Brinton RD: Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. Ann N Y Acad Sci 2003, 1052:57-74.

218. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, Kuller LH, Lipton RB, et al: Estrogen for Stroke Trial (WEST). Arch Intern Med 2008, 168(12):1271-1275.

219. Arnold AP: Sex chromosomes and brain gender. Nat Rev Neurosci 2004, 5(9):701-708.

220. Arnold AP, Burgoyne PS: Are XX and XY brain cells intrinsically different? Trends Endocrinol Metab 2004, 15(1):6-11.

221. Burgoyne PS, Lovell-Badge R, Rattigan A: Evidence that the testis determination pathway interacts with a non-dosage compensated, X-linked gene. Int J Dev Biol 2001, 45(3):509-512.

222. Barlow PS, Lovell-Badge R, Rattigan A: A model system for study of sex chromosome effects on sexually dimorphic neural and behavioral traits. J Neurosci 2002, 22(20):9005-9014.

223. Markham JA, Jurgens HA, Auger CJ, De Vries GJ, Arnold AP, Juraska JM: Sex differences in mouse cortical thickness are independent of the complement of sex chromosomes. Neuroscience 2003, 116(1):71-75.

224. Wagner CR, Xu J, Puhl JL, Quadras PS, De Vries GJ, Arnold AP: Neonatal mice possessing an Sry transgene show a masculinized pattern of progestrone receptor expression in the brain independent of sex chromosome status. Endocrinology 2004, 145(3):1046-1049.

225. Cua DJ, Hinton DR, Stohlman SA: Self-antigen-induced Th2 responses in experimental allergic encephalomyelitis (EAE)-